Piper Sandler Reiterates Overweight Rating on Poseida Therapeutics, Inc (PSTX)

September 30, 2024 7:55 AM EDT Send to a Friend
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $10.00 price target on Poseida Therapeutics, Inc (NASDAQ: PSTX).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login